{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:49:39Z","timestamp":1792687779762,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:p>Cardiovascular diseases (CVD) are the leading cause of death globally, followed by cancer. Angiotensin II contributes greatly to CVD pathogenesis, and Angiotensin II receptor blockers (ARBs) constitute a mainstay in hypertension and CVD management. However, the relationship between ARBs and cancer initiation is controversial, with no clear data in Lebanon. Therefore, our study aimed to determine the association between ARBs intake and lung, bladder, and colorectal cancers development in the Lebanese population. A retrospective study was conducted on 709 subjects divided into 2 main groups: Control (subjects without cancer; n = 177), and Cases (patients with cancer (n = 532): lung, bladder, or colorectal), taking ARBs (n = 236, (n = 121 in control and n = 115 in cases)) or not (n = 473). Collected information included the patients demographics, comorbidities, cancer\u2019s risk factors, and ARBs dose and duration intake. Bivariate, multivariate, and binary logistic analyses were enrolled. ARBs use was significantly protective (<jats:italic toggle=\"yes\">P<\/jats:italic> value = 0.000) against overall cancer development (odds ratio [OR] = 0.127) and against each, lung (OR &lt; 1), bladder (OR &lt; 1), and colorectal cancers (OR &lt; 1). A duration-response relationship was established. This protective effect and the time-dependent relationship remained unchanged after omitting the most relevant risk factors. In summary, a significant overall protective effect of ARBs against lung, bladder and colorectal cancers was found. This beneficial response was time-dependent. These results can guide patients on treatment options and clinicians for informed decision-making.<\/jats:p>","DOI":"10.1097\/md.0000000000034901","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T14:09:56Z","timestamp":1694182196000},"page":"e34901","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["The association between angiotensin receptor blockers and lung, bladder, and colon cancer development: A 10-year multicentric retrospective Lebanese study"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4316-8598","authenticated-orcid":false,"given":"Yara G.","family":"Dagher","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"El Helou","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen G.","family":"Haifa","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam G.","family":"Chalhoub","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita T.","family":"Boulos","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachir","family":"Atallah","sequence":"additional","affiliation":[{"name":"Statistics, Lebanese University, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Nasr","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"},{"name":"Hematology-Oncology Department, Hotel Dieu DE France, Achrafieh, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"Kassab","sequence":"additional","affiliation":[{"name":"National Center of Pharmacovigilance, Faculty of Pharmacy, Lebanese University, Hadath, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna N.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"},{"name":"Basic Sciences Department, Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon"},{"name":"Foundation-Medical Research Institutes (F-MRI), Beirut, Lebanon\/Geneva, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","article-title":"Primary prevention of cardiovascular disease: a review of contemporary guidance and literature.","volume":"6","author":"Stewart","year":"2017","journal-title":"JRSM Cardiovasc Dis"},{"key":"R2-20250504","first-page":"123","article-title":"Angiotensin II receptor blockers.","volume":"16","author":"Barreras","year":"2003","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11906-999-0036-3","article-title":"Mechanism of action of angiotensin-receptor blocking agents.","volume":"1","author":"Siragy","year":"1999","journal-title":"Curr Hypertens Rep"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"18014","DOI":"10.1038\/nrdp.2018.14","article-title":"Hypertension.","volume":"4","author":"Oparil","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1097\/HJH.0b013e3283649b33","article-title":"Angiotensin-II induced hypertension and renovascular remodelling in tissue inhibitor of metalloproteinase 2 knockout mice.","volume":"31","author":"Pushpakumar","year":"2013","journal-title":"J Hypertens"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jch.13531","article-title":"First-line treatment of essential hypertension: a real-world analysis across four antihypertensive treatment classes.","volume":"21","author":"Stapff","year":"2019","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study.","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40264-014-0239-7","article-title":"The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.","volume":"38","author":"Abraham","year":"2015","journal-title":"Drug Saf"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0971-5916.195022","article-title":"Angiotensin receptor blockers & endothelial dysfunction: possible correlation and therapeutic implications.","volume":"144","author":"Radenkovic","year":"2016","journal-title":"Indian J Med Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-7954-12-4","article-title":"Cancer trends in Lebanon: a review of incidence rates for the period of 2003-2008 and projections until 2018.","volume":"12","author":"Shamseddine","year":"2014","journal-title":"Popul Health Metr"},{"key":"R12-20250504","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview.","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12885-017-3304-7","article-title":"Proportion of cancer in a Middle eastern country attributable to established risk factors.","volume":"17","author":"Charafeddine","year":"2017","journal-title":"BMC Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jcm10040771","article-title":"Antihypertensive drugs and the risk of cancer: a nationwide cohort study.","volume":"10","author":"Cho","year":"2021","journal-title":"J Clin Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e0263461","DOI":"10.1371\/journal.pone.0263461","article-title":"Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: meta-regression analysis of randomized trials.","volume":"17","author":"Sipahi","year":"2022","journal-title":"PLoS One"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ijcard.2014.11.031","article-title":"A review of clinical studies on angiotensin II receptor blockers and risk of cancer.","volume":"177","author":"D\u00e9zsi","year":"2014","journal-title":"Int J Cardiol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e3600","DOI":"10.1097\/MD.0000000000003600","article-title":"Angiotensin II receptor blockers and cancer risk: a meta-analysis of randomized controlled trials.","volume":"95","author":"Zhao","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/jch.14187","article-title":"Effect of angiotensin receptor blockers on the development of cancer: a nationwide cohort study in korea.","volume":"23","author":"Jung","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3961\/jpmph.20.405","article-title":"Association between angiotensin II receptor blockers and the risk of lung cancer among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort.","volume":"53","author":"Moon","year":"2020","journal-title":"J Prev Med Public Health"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1245\/s10434-012-2568-z","article-title":"Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer.","volume":"19","author":"Yuge","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1245\/s10434-016-5534-3","article-title":"Prognostic impact of renin-angiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy.","volume":"24","author":"Yoshida","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"e50893","DOI":"10.1371\/journal.pone.0050893","article-title":"Long-term use of angiotensin receptor blockers and the risk of cancer.","volume":"7","author":"Azoulay","year":"2012","journal-title":"PLoS One"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s10552-015-0617-1","article-title":"Angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis.","volume":"26","author":"Dai","year":"2015","journal-title":"Cancer Causes Control"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/HYPERTENSIONAHA.120.15317","article-title":"ACE (angiotensin-converting enzyme) inhibitors\/angiotensin receptor blockers are associated with lower colorectal cancer risk: a territory-wide study with propensity score analysis.","volume":"76","author":"Cheung","year":"2020","journal-title":"Hypertension"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci Transl Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:28:49Z","timestamp":1746325729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":26,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034901","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]}}}